SPECC1L-related hypertelorism syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:1519OMIM:145420Q87.0
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

SPECC1L-related hypertelorism syndrome, also known as Opitz BBB/G syndrome autosomal dominant (formerly classified under Orphanet code 1519), is a rare genetic condition caused by mutations in the SPECC1L gene. This syndrome is characterized by prominent facial features including hypertelorism (widely spaced eyes), which is the hallmark of the condition. It falls within the spectrum of disorders historically grouped under Opitz G/BBB syndrome, which affects multiple body systems during embryonic development. The condition primarily affects craniofacial structures, with patients commonly presenting with hypertelorism, broad nasal bridge, cleft lip and/or cleft palate, and other midline developmental defects. Additional features may include laryngotracheoesophageal abnormalities (such as laryngeal cleft or swallowing difficulties), hypospadias in males, and congenital heart defects. Intellectual development is variable, with some individuals having normal cognition while others may experience mild developmental delays. Treatment is symptomatic and supportive, tailored to the specific manifestations in each patient. Surgical correction may be required for cleft lip/palate, hypospadias, or cardiac defects. Speech therapy, feeding support, and developmental interventions may be beneficial. A multidisciplinary approach involving geneticists, craniofacial surgeons, cardiologists, urologists, and speech-language pathologists is recommended for comprehensive management. Genetic counseling is important for affected families given the autosomal dominant inheritance pattern.

Also known as:

Clinical phenotype terms— hover any for plain English:

Shawl scrotumHP:0000049Ectopic kidneyHP:0000086Widow's peakHP:0000349
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for SPECC1L-related hypertelorism syndrome.

View clinical trials →

No actively recruiting trials found for SPECC1L-related hypertelorism syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the SPECC1L-related hypertelorism syndrome community →

No specialists are currently listed for SPECC1L-related hypertelorism syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to SPECC1L-related hypertelorism syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open SPECC1L-related hypertelorism syndromeForum →

No community posts yet. Be the first to share your experience with SPECC1L-related hypertelorism syndrome.

Start the conversation →

Latest news about SPECC1L-related hypertelorism syndrome

No recent news articles for SPECC1L-related hypertelorism syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about SPECC1L-related hypertelorism syndrome

What is SPECC1L-related hypertelorism syndrome?

SPECC1L-related hypertelorism syndrome, also known as Opitz BBB/G syndrome autosomal dominant (formerly classified under Orphanet code 1519), is a rare genetic condition caused by mutations in the SPECC1L gene. This syndrome is characterized by prominent facial features including hypertelorism (widely spaced eyes), which is the hallmark of the condition. It falls within the spectrum of disorders historically grouped under Opitz G/BBB syndrome, which affects multiple body systems during embryonic development. The condition primarily affects craniofacial structures, with patients commonly prese

How is SPECC1L-related hypertelorism syndrome inherited?

SPECC1L-related hypertelorism syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does SPECC1L-related hypertelorism syndrome typically begin?

Typical onset of SPECC1L-related hypertelorism syndrome is neonatal. Age of onset can vary across affected individuals.